Gallium nitrate in malignant lymphoma: a Southwest Oncology Group study

Cancer Treat Rep. 1983 Sep;67(9):823-5.


Gallium nitrate was evaluated by the Southwest Oncology Group in 38 patients with malignant lymphoma, both Hodgkin's disease and non-Hodgkin's lymphoma. Treatment was administered every 2 weeks at a dose of 700 mg/m2, with acceptable toxicity. Seven partial responses (18%) with a duration of 3-11 months were seen: one of seven in Hodgkin's disease and six of 26 in diffuse non-Hodgkin's lymphoma. No responses were noted in nodular types. Gallium nitrate has activity in lymphomas and should be combined with more active drugs for patients who have undergone less intensive prior therapy.

Publication types

  • Research Support, U.S. Gov't, P.H.S.

MeSH terms

  • Adolescent
  • Adult
  • Aged
  • Gallium / administration & dosage
  • Gallium / adverse effects
  • Gallium / therapeutic use*
  • Hodgkin Disease / drug therapy*
  • Humans
  • Lymphoma / drug therapy*
  • Middle Aged


  • Gallium
  • gallium nitrate